← ANALYST RATINGS · TIPRANKS
Dyne Therapeutics (DYN): analyst forecast and price target
Analyst consensus
Strong Buy13 Buy0 Hold1 Sell
Ratings of 14 analysts in the last 3 months12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $34.67, the highest $50.00, the lowest $10.00. The average is +143.3% from the last price of $14.25.
Analyst ratings 16
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $16.50 → $14.50−12.1% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $16.50 → $14.00−15.2% | Hold | −1.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $16.00 → $14.00−12.5% | Hold | −1.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $16.00 → $14.00−12.5% | Hold | −1.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $16.50 → $14.50−12.1% | Hold | +1.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $16.00 → $14.00−12.5% | Hold | −1.8% | Reiterated | 17.10.26on TipRanks 07:06 | — | |
| Francois Brisebois★★★★★★★★★★#2595 · hits 43% · avg +5.9% | LifeSci Capital | $40.00 | Buy | +180.7% | Reiterated | 30.09.26on TipRanks 09:15 | −0.4%next day −2.0% · 5 days −2.8% | ↗ |
| Paul Matteis★★★★★★★★★★#473 · hits 53% · avg +17.6% | Stifel Nicolaus | $37.00 | Buy | +159.6% | Reiterated | 30.09.26on TipRanks 08:30 | −0.4%next day −2.0% · 5 days −2.8% | ↗ |
| Andrew Fein★★★★★★★★★★#267 · hits 52% · avg +23.7% | H.C. Wainwright | $50.00 → $32.00−36.0% | Buy | +124.6% | Reiterated | 30.09.26on TipRanks 06:20 | −0.4%next day −2.0% · 5 days −2.8% | ↗ |
| Edward Tenthoff★★★★★★★★★★#3650 · hits 41% · avg +3.5% | Piper Sandler | $47.00 | Buy | +229.8% | Reiterated | 29.09.26on TipRanks 06:50 | −0.6%next day −0.4% · 5 days −6.9% | ↗ |
| Martin Auster★★★★★★★★★★#1128 · hits 51% · avg +16.1% | Raymond James | $37.00 | Buy | +159.6% | Reiterated | 23.09.26on TipRanks Sep 24 05:10 | −4.6%next day +1.8% · 5 days −0.1% | ↗ |
| Michael Ulz★★★★★★★★★★#6183 · hits 43% · avg +0.9% | Morgan Stanley | $45.00 → $36.00−20.0% | Buy | +152.6% | Reiterated | 09.09.26on TipRanks 07:55 | −5.0%next day −3.4% · 5 days −8.7% | ↗ |
| Brian Skorney★★★★★★★★★★#12116 · hits 37% · avg −5.6% | Robert W. Baird | $30.00 → $26.00−13.3% | Buy | +82.5% | Reiterated | 09.09.26on TipRanks 07:08 | −5.0%next day −3.4% · 5 days −8.7% | ↗ |
| Tessa Romero★★★★★★★★★★#805 · hits 57% · avg +21.7% | J.P. Morgan | $10.00 | Sell | −29.8% | Downgrade | 08.09.26on TipRanks Sep 10 14:35 | −15.8%next day −5.0% · 5 days −10.7% | ↗ |
| Luca Issi★★★★★★★★★★#11187 · hits 39% · avg −2.1% | RBC Capital | $35.00 → $30.00−14.3% | Buy | +110.5% | Reiterated | 08.09.26on TipRanks Sep 9 07:30 | −15.8%next day −5.0% · 5 days −10.7% | ↗ |
| Andrew Tsai★★★★★★★★★★#339 · hits 63% · avg +29.9% | Jefferies | $50.00 | Buy | +250.9% | Reiterated | 08.09.26on TipRanks 08:25 | −15.8%next day −5.0% · 5 days −10.7% | ↗ |
| Keay Nakae★★★★★★★★★★#3914 · hits 40% · avg +3.0% | Chardan Capital | $38.00 | Buy | +166.7% | Reiterated | 29.07.26on TipRanks 21:50 | +0.8%next day −2.9% · 5 days −3.0% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 28.07.26on TipRanks Jul 29 03:15 | +0.8%next day −1.6% · 5 days −3.8% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $33.00 | Buy | +131.6% | Reiterated | 27.07.26on TipRanks 14:17 | +4.8%next day +0.8% · 5 days −4.0% | ↗ |
| Eric Schmidt FCA★★★★★★★★★★#358 · hits 51% · avg +84.1% | Cantor Fitzgerald | — | Buy | — | Initiated | 23.07.26on TipRanks Jul 24 05:10 | +4.2%next day +2.2% · 5 days +7.2% | ↗ |
| Unknown Analyst | Guggenheim | $50.00 | Buy | +250.9% | Reiterated | 30.06.26on TipRanks Jul 3 07:09 | +3.7%next day −1.8% · 5 days +7.5% | ↗ |
| William Pickering★★★★★★★★★★#5908 · hits 58% · avg +1.8% | Bernstein | $23.00 → $24.00+4.3% | Hold | +68.4% | Assigned | 13.05.26on TipRanks 06:35 | −0.2%next day −1.7% · 5 days −4.6% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Dyne Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $34.67 at a price of $16.11 (+115.2%); now: $34.67 at $14.25 (+143.3%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 24 | 20 | 24 | 13 | 17 | 12 |
| Buy | 0 | 1 | 6 | 6 | 7 | 2 |
| Hold | 2 | 1 | 3 | 2 | 2 | 0 |
| Sell | 0 | 0 | 0 | 0 | 1 | 1 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.91 (from $-1.09 to $-0.73). Last quarter: $-1.08.
Best top-analyst consensus in the sector · Healthcare
About Dyne Therapeutics
- CEO: John G. Cox
- Employees: 289
- 1560 Trapelo Road, Waltham, MA, 02451, US
- www.dyne-tx.com
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
Data from the stock’s TipRanks forecast page, read 8 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗